Clinical Trial Update: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Phase 1]

View source ↗

Summary

Phase I study of percutaneous valrubicin for upper tract urothelial carcinoma has completed its Phase I evaluation. The trial status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Valrubicin (valrubicin)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Urothelial Carcinoma | Phase 1 | Status: COMPLETED